Evidence-based medicine is advocated by WHO and adopted by developed countries for many years. In China, however, the selection of essential medicine and various medical insurance reimbursement schemes medicine is usually based on experts’ experience of prescription practice which is under heavy critics resulting from the lack of related comparative efficacy and evidence-based research. The efficacy of Jian’ganle in prevention of drug-induced liver injury(DILI) caused by antituberculotics was evaluated in this study by comparison with Hugan Pian, glucuronolactone and reduced glutathione. Evidence was provided for relevant sectors such as Ministry for Human Resources and Social Security of the People’s Republic of China and National Health and Family Planning Commission of the People’s Republic of China to select and renew the Essential Medicine List(EML), the new rural cooperative medical scheme in China(NRCMS) list or the reimbursement list of industrial injury insurance. A total of 189 patients with initial pulmonary tuberculosis were divided into four groups who took antituberculotics combined with Jian’ganle, Hugan Pian, glucuronolactone and reduced glutathione respectively. Their liver function profile including alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(TBIL), direct bilirubin(DBIL), total protein(TP), albumin(A) and globulin(G) were detected at admission as baseline and after treatment. The Jian’ganle group was compared with the three others by chi-square tests. In an aspect of maintaining bilirubin indexes normal, Jian’ganle was more efficacious than glucuronolactone. And Jian’ganle had a little more efficacy than reduced glutathione to maintain protein indexes normal as well. And the therapeutic regimen of antituberculotics combined with Jian’ganle was the best in treating tuberculosis and preventing DILI at the same time. The study showed that among the four hepatinicas which demonstrated similar prevention of DILI caused by antituberculotics, Jian’ganle has more advantages over the three others to some extent, which provides a reliable basis for health sectors to select and renew the EML, NRCMS List or the reimbursement list of industrial injury insurance. Ev China-based medicine is advocated by WHO and adopted by developed countries for many years. In China, however, the selection of essential medicine and various medical insurance reimbursement schemes medicine is usually based on experts’ experience of prescription practice which is under heavy criticsics from the lack of related comparative efficacy and evidence-based research. The efficacy of Jian’ganle in prevention of drug-induced liver injury (DILI) caused by antituberculotics was evaluated in this study by comparison with Hugan Pian, glucuronolactone and reduced glutathione. Evidence was provided for relevant sectors such as Ministry for Human Resources and Social Security of the People’s Republic of China and National Health and Family Planning Commission of the People’s Republic of China to select and renew the Essential Medicine List (EML), the new rural cooperative medical scheme in China (NRCMS) list or the reimbursement list of industrial injury insurance. A total of 1 89 patients with initial pulmonary tuberculosis were divided into four groups who took antituberculotics combined with Jian’ganle, Hugan Pian, glucuronolactone and reduced glutathione respectively. Their liver function profile including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin ), direct bilirubin (DBIL), total protein (TP), albumin (A) and globulin (G) were detected at admission as baseline and after treatment. The Jian’ganle group was compared with the three others by chi-square tests. And an aspect of maintaining bilirubin indexes normal, Jian’ganle was more efficacious than glucuronolactone. And Jian’ganle had a little more efficacy than reduced glutathione to maintain protein indexes normal as well. And the therapeutic regimen of antituberculotics combined with Jian’ganle was the best in treating tuberculosis and preventing DILI at the same time. The study showed that among the four hepatinicas which show similar to prevention of DILI caused by antituberculotics, Jian’ganle has more advantages over the three others to some extent, which provides a reliable basis for health sectors to select and renew the EML, NRCMS List or the reimbursement list of industrial injury insurance.